Updates

Benchmark

January 2016

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Benchmark has returned from suspension and completed the acquisition of INVE Aquaculture for £227m (£199m cash plus £28m in shares) together with a placing of 216m shares at 86p to raise £186m. The deal is a reverse takeover by the larger INVE and represents 12.1x INVE's post tax profit, making it eps enhancing from day one.INVE is a specialist manufacturer of aquaculture nutrition for shrimp and marine species of fin fish. It supplies live feed (artemia), replacement diets and health products that aim to reduce disease and enhance immunity, through the application of probiotics and immuno-stimulants. It has a 20%+ share in the global shrimp and marine fin fish hatchery/nursery larval diets segments. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Vislink

Patisserie Holdings - Records 9th consecutive year of growth

Benchmark - Woodford overhang clears (July 2019)

Benchmark (July 2018)

Benchmark - Product launches set for big uptick (December 2017)

Benchmark (November 2017)

Benchmark - Outer year forecasts will rise once capacity comes on stream (September 2016)

Benchmark (August 2016)

Benchmark - Down but certainly not out (March 2016)

Benchmark - Reverse takeover talks (November 2015)

Benchmark - Buys tilapia breeding business for £11m (September 2015)

Benchmark (July 2015)

Benchmark (May 2015)

Benchmark - Acquires veterinary training business (March 2015)

Benchmark (February 2015)

Benchmark (December 2014)

Benchmarck - Exciting new vaccine for cats (September 2014)

Benchmark - Not long for the new products to emerge (July 2014)

Benchmark - Top dog in aquafarming sector (May 2014)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X